Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Biotechnology

Healthcare
$247.77 +0.02%

+$0.05 today

Market cap
$15.90B
Beta
0.33
P/E (TTM)
476.3
EPS (TTM)
$0.48
52W Low $105.00High $243.32

Volume 0.72M

Average 0.92M

JAZZ Sales of Investments

Cash received from selling or redeeming investments.

Jazz Pharmaceuticals plcNASDAQ: JAZZ

Sales of Investments · Q3 FY2026 · quarter ended Sep 2026

Sales of investments dips below year-ago levels

Q3 FY2026 sales of investments of $300M fell 25.0% year over year, behind the +92.5% change in trailing-twelve-month sales of investments. Sequentially, it fell 58.3% from the prior quarter. Over 3 fiscal years it compounded at +183.0% a year.

Context

  • Sales of investments amounted to 31.9% of revenue in FY2025, up 11.1 pp from a year earlier.
  • Sales of investments increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -25.0% toward the trailing-twelve-month pace of +92.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$300M-58.3% QoQ
Last fiscal yearDec 2025
$1.36B+60.9% YoY
LTMSep 2026
$2.83B+92.5% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.0%——
1 year+60.9%——
3-year CAGR+183.0%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
1.36B USD
Year-over-year change
+60.9%
4-year CAGR
+5.6%

Sales of Investments vs competitors

How JAZZ compares with its peers on the latest reported figures

  • JAZZ's LTM Sep 2026 sales of investments of $2.83B is the largest of the 9 companies compared; the peer median is $511.27M.
  • Its year-over-year change of +92.5% is the 3rd highest of 8, against a peer median of +36.8%.
  • Sales of investments amounts to 60.0% of revenue for JAZZ, versus a peer median of 62.1%.
JAZZ Competitors Peer median
Sales of Investments for JAZZ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JAZZJazz Pharmaceuticals plcLTM Sep 2026$2.83B +92.5%+183.0%60.0%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$2.8B +161.1%+28.7%75.6%
GMABGenmab A/SLTM Jun 2026$2.03B —-28.7%49.1%
LEGNLegend Biotech CorporationLTM Sep 2026$1.02B -79.1%+105.5%75.2%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 2026$738.02M +182.1%+17.2%254.0%
INCYIncyte CorporationLTM Jun 2026$284.53M +36.8%+53.2%4.9%
TGTXTG Therapeutics, Inc.LTM Sep 2026$254.15M -9.6%+39.6%28.3%
MGNXMacroGenics, Inc.LTM Mar 2026$125.44M -4.7%-21.0%79.9%
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 2026$68.94M +39.8%—7.2%
Peer median (excluding JAZZ) $511.27M+36.8%+28.7%62.1%

Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(329.67M)(224.06M)414.83M560.12M(356.15M)
Depreciation & Amortization552.48M629.47M638.7M660.07M696.3M
Deferred Income Tax69.2M(292.25M)(260.22M)(208.33M)(444.97M)
Stock-Based Compensation189.01M222M226.84M248.05M291.13M
Change in Working Capital(47.95M)9.91M(204.44M)(76.72M)18.9M
Accounts Receivables(92.74M)(90.14M)(51.88M)(21.12M)(106.28M)
Inventory(48.86M)(49.64M)(13.42M)(45.54M)(86.04M)
Accounts Payables57.02M(11.23M)9.6M(20.07M)39.85M
Other Working Capital36.62M160.91M(148.74M)10.01M171.37M
Other Non-Cash Items345.44M926.92M276.29M212.72M1.15B
Operating Cash Flow778.51M1.27B1.09B1.4B1.36B
Capital Expenditures(45.53M)(498.19M)(23.96M)(48.07M)(209.75M)
Acquisitions (Net)(6.23B)53M00(858.05M)
Purchases of Investments(26.82M)(61.04M)(390.1M)(1.31B)(1.83B)
Sales of Investments1.1B60M270M845M1.36B
Other Investing Activities(17.89M)0(19M)(10M)(122.83M)
Investing Cash Flow(5.21B)(446.23M)(163.06M)(508.2M)(1.51B)
Debt Repayment3.87B(582.01M)(31M)374.77M(781M)
Common Stock Issued135.26M046.46M20.65M107.86M
Common Stock Repurchased0(54K)(269.76M)(311.43M)(125.02M)
Dividends Paid00000
Other Financing Activities(35.6M)(45.44M)(50.95M)(63.47M)(75.22M)
Financing Cash Flow3.97B(529.49M)(305.25M)20.52M(873.38M)
Effect of Forex Changes(3.21M)(6.22M)1.14M(1.68M)6.56M
Net Change in Cash(466.32M)290.03M624.83M906.55M(1.02B)
Free Cash Flow732.98M773.78M1.07B1.35B1.15B

Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Intrinsic Alpha fair value

Locked

Current Price

$247.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.